Convalescent plasma is still in demand. But there are caveats – ABC News

This is a Kaiser Health News story.
Six months after it was controversially hailed by Trump administration officials as a breakthrough therapy to fight the worst effects of covid-19, convalescent plasma appears to be on the ropes.
The treatment that infuses blood plasma from recovered covid patients into people newly infected in hopes of boosting their immune response has not lived up to early hype. Some high-profile clinical trials have shown disappointing results. Demand from hospitals for the…

Click here to view the original article.